JNJ Sep 2024 180.000 call
| Previous close | 0.2600 |
| Open | 0.2600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 180.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.2600 - 0.2600 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksJohnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Reuters
UPDATE 1-Johnson & Johnson to acquire Proteologix for $850 million
Johnson & Johnson said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic dermatitis treatments. Proteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.
ReutersJohnson & Johnson to acquire Proteologix for $850 million
Proteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.
